News

Daibochi said construction of the new plant, which is in line with the company’s expansion and positive outlook, will enable it to expand its in-house film-making and metallizing

The extended collaboration leverages new drug-development model that combines basic and clinical research and is expected to cut short the time required to develop new therapeutic candidates. The

Rayos is a proprietary delayed-release formulation of low-dose prednisone and is known as Lodotra outside the US. Horizon Pharma chairman, president and chief executive officer Timothy Walbert said

AMRI’s ALB 109564(a) is a novel analog designed to prevent cell mitosis thereby killing cancer cells. AMRI chairman and CEO Thomas D’Ambra said, "The recent formation of Chai

Embryonic stem cell-based trial was designed to assess the hESC-derived ACT’s retinal pigment epithelial (RPE) cells in patients with severe myopia (nearsightedness). ACT chairman and CEO Gary Rabin

The acquired products include drugs for the treatment of dermatology, respiratory and autoimmune diseases. Innovus said as none of the drugs are currently being marketed, the company is

CP024 growth hormone nasal spray was safe and well tolerated in the study that administered six dose levels of CP024 in healthy subjects. Pharmacokinetics demonstrated by the nasal

Julphar said it has invested ETB170m ($9.13m) in constructing new facility, which was built in conjunction with its local Ethiopian partner, Medtech, and occupies 40,000 ft² space. The

A Gilead subsidiary acquired all YM’s outstanding common shares as per the terms of a plan of arrangement. Thus, YM has become a wholly-owned subsidiary of Gilead. YM